Award
National Institute of Neurological Disorders and Stroke 5U01NS123252-04
Antiglutamatergic Therapy to Protect the Brain Against Nerve Agents
Recipient
National Institute of Neurological Disorders and Stroke (NINDS), NIH
Award Amount
$721,888.00
Ceiling
$721,888.00
Awarded
August 04, 2025
Identifier
5U01NS123252-04
NIH awarded a project to develop antiglutamatergic therapy as a medical countermeasure against nerve agent toxicity, focusing on neuroprotection and behavioral outcomes in rat models.
Description
The project involves testing antiglutamatergic therapy in rats exposed to soman, a nerve agent. The research aims to develop effective medical countermeasures against nerve agent toxicity. The project is funded by NIH, with a focus on brain disorders, biodefense, and related countermeasures. The project includes studies on young, adult, and aged rats, with comparisons to existing treatments like midazolam. The project emphasizes long-term neuroprotection and behavioral outcomes.